Osvaldo Soares de Araújo Júnior
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Osvaldo Soares de Araújo Júnior has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Souza Sá Filho
Universidade Evangélica de Goiás, Anápolis, Brasil
1 shared publication - Carly de Faria Coelho
Laboratory of Biophotonics and Experimental Therapeutics—LABITEX, Universidade Evangélica de Goiás—Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, Brazil
1 shared publication - Deise Aparecida de Almeida Pires Oliveira
Human Movement and Rehabilitation Graduate Program, Evangelical University of Goiás (UniEVANGELICA), Anápolis 75083-515, GO, Brazil
1 shared publication - Gustavo Ribeiro Godinho de Sousa Teixeira1 shared publication
- Larissa Gomes dos Santos
Graduanda em Medicina Universidade Evangélica de Goiás. (UniEVANGÉLICA) Avenida Universitária Km 3 5 Cidade Universitária Anápolis -GO 75083-515. CEP
1 shared publication - Lucas Danilo Dias
Laboratório de Novos Materiais,Universidade Evangelica de Goiás,Anapolis,Brazil, Brazil
1 shared publication
Latest Publications
- Open Access
- 19 November 2024
- Vol. 16 (11) , e6391
A eficácia da telerreabilitação na doença de Parkinson: uma revisão integrativa
- 19 November 2024
- Vol. 16 (11) , e6391
Open AccessA eficácia da telerreabilitação na doença de Parkinson: uma revisão integrativa
- Open Access
The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials
Generalized Anxiety Disorder (GAD) is a common psychiatric condition characterized by persistent and excessive worry, often accompanied by dysautonomic symptoms that significantly impact patients’ well-being. Cannabidiol (CBD), a non-psychoactive compound derived from cannabis, has shown potential as an anxiolytic through its partial agonism of the 5HT-1A receptor and its negative allosteric modulation of CB1 receptors, which may help mitigate the anxiogenic effects of tetrahydrocannabinol (THC). This study evaluates the impact of CBD on individuals diagnosed with various anxiety disorders, comparing its effects to placebo and conventional pharmaceutical treatments through a systematic review of randomized controlled trials (RCTs). A systematic search of RCTs published between 2013 and 2023 was conducted across three databases using the terms “cannabidiol” and “anxiety”. Out of the 284 articles identified, 11 met the eligibility criteria. The studies reviewed varied widely in terms of the types of anxiety disorders and CBD dosages examined, leading to results that were often contradictory. Despite these conflicting outcomes, the data suggest that CBD may reduce anxiety with minimal adverse effects when compared to a placebo. However, further RCTs with improved methodologies, encompassing a broad range of doses and continuous CBD administration across specific anxiety disorders, are needed. Unlike previous studies and meta-analyses, this review encompasses a broader spectrum of anxiety disorders and a variety of study designs and dosages, providing a more nuanced understanding of CBD’s potential efficacy across different conditions.
Open AccessThe Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials
Generalized Anxiety Disorder (GAD) is a common psychiatric condition characterized by persistent and excessive worry, often accompanied by dysautonomic symptoms that significantly impact patients’ well-being. Cannabidiol (CBD), a non-psychoactive compound derived from cannabis, has shown potential as an anxiolytic through its partial agonism of the 5HT-1A receptor and its negative allosteric modulation of CB1 receptors, which may help mitigate the anxiogenic effects of tetrahydrocannabinol (THC). This study evaluates the impact of CBD on individuals diagnosed with various anxiety disorders, comparing its effects to placebo and conventional pharmaceutical treatments through a systematic review of randomized controlled trials (RCTs). A systematic search of RCTs published between 2013 and 2023 was conducted across three databases using the terms “cannabidiol” and “anxiety”. Out of the 284 articles identified, 11 met the eligibility criteria. The studies reviewed varied widely in terms of the types of anxiety disorders and CBD dosages examined, leading to results that were often contradictory. Despite these conflicting outcomes, the data suggest that CBD may reduce anxiety with minimal adverse effects when compared to a placebo. However, further RCTs with improved methodologies, encompassing a broad range of doses and continuous CBD administration across specific anxiety disorders, are needed. Unlike previous studies and meta-analyses, this review encompasses a broader spectrum of anxiety disorders and a variety of study designs and dosages, providing a more nuanced understanding of CBD’s potential efficacy across different conditions.